What Is Acomplia / Rimonabant / Zimulti?
Rimonabant, discovered and developed by French pharmaceutical company Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors. Rimonabant is already on the market in Europe, being sold under the trade name Acomplia, and is awaiting approval in the United States.The FDA would not permit rimonabant to be sold as Acomplia in the U.S., and Sanofi is now hoping to market it in the United States as Zimulti. Rimonabant works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.
